Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: A comparative review

Clinical Pharmacokinetics

Volumn 47, Issue 4, 2008, Pages 217-230

  Devillier, Philippe ^a,b   Roche, Nicolas ^a   Faisy, Christophe ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b FOCH HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CETIRIZINE; CIMETIDINE; CYTOCHROME P450; DESLORATADINE; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; LEVOCETIRIZINE; LOPINAVIR PLUS RITONAVIR; LORATADINE; PILSICAINIDE; PLACEBO; RIFAMPICIN; RITONAVIR;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; ASTHENIA; CELL COUNT; CHRONIC IDIOPATHIC URTICARIA; CLINICAL TRIAL; COGNITIVE DEFECT; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; FATIGUE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; INFLAMMATORY CELL; MEMORY DISORDER; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QRS COMPLEX; QUALITY OF LIFE; RECEPTOR AFFINITY; REVIEW; SCORING SYSTEM; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYMPTOM; TH2 CELL; URINARY EXCRETION; URTICARIA;

CETIRIZINE; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TERFENADINE; URTICARIA;

EID: 40549139803     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847040-00001     Document Type: Review

References (148)

1. Clarinex [prescribing information]. Kenilworth (NJ): Schering-Plough Corporation, 2005
2. Aerius [prescribing information]. Brussels: Schering-Plough Europe, 2006
3. Allegra [prescribing information]. Bridgewater (NJ): Sanofi-Aventis US, LLC, 2007
4. Telfast 120 and 180 [prescribing information; online]. Guildford: Sanofi-Aventis, 2007 Feb 20. Available from URL: http://emc.medicines.org.uk/ emc/assets/c/html/displaydoc.asp?.documentid=6659 [Accessed 2008 Feb 18]
5. Telfast 30 [prescribing information; online]. Guildford: Sanofi-Aventis, 2007 Apr 17. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?.documentid=14464 [Accessed 2008 Feb 18]
6. Xyzal [prescribing information]. Atlanta (GA): UCB, Inc., 2007
7. Xyzal [prescribing information; online]. Slough: UCB Pharma Limited, 2007 Jul. Available from URL: http://emc.medicines.org.uk/industry/default.asp?. page=displaydoc.asp&documentid=19877 [Accessed 2008 Feb 18]
8. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: S147-334
9. 1-receptor gene. Hum Genet 1994; 94: 186-8
10. 2 receptor. Proc Natl Acad Sci U S A 1991; 88: 429-33
11. 3 receptor. Mol Pharmacol 1999; 55: 1101-7
12. Oda T, Morikawa N, Saito Y, et al. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275: 36781-6
13. 2 receptor-deficient mice. J Clin Invest 2000; 105: 1741-9
14. 3 receptors. J Pain 2005; 6: 193-200
15. 3 antagonists. Bioorg Med Chem 2005; 13: 5647-57
16. 3 receptor decreases caloric intake in higher mammalian species. Biochem Pharmacol 2007; 73: 1237-42
17. 3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Nat Acad Sci U S A 2006; 103: 13866-71
18. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004; 25: 618-25
19. 3 receptor subtypes. Br J Pharmacol 1992; 107: 919-23
20. 3 receptors in the trachea. Br J Pharmacol 1994; 111: 445-54
21. Li M, Luo X, Chen L, et al. Co-localization of histamine and dopamine-β-hydroxylase in sympathetic ganglion and release of histamine from cardiac sympathetic terminals of guinea-pig. Auton Autacoid Pharmacol 2004; 23: 327-33
22. 3 heteroreceptors. Fundam Clin Pharmacol 1994; 8: 128-37
23. 3 receptors in -human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004; 484: 83-9
24. 4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005; 26: 462-9
25. 4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 2003; 307: 1072-8
26. 4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 2006; 176: 7062-70
27. 1 receptors in scratching induced by histamine receptor agonists in BalbC mice. Br J Pharmacol 2004; 142: 374-80
28. 4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119: 176-83
29. 1-antihistamines. N Engl J Med 2004; 351: 2203-17
30. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006; 533: 69-76
31. 1 receptor antagonists. Eur Pharmacol 2000; 387: R5-7
32. MacGlashan Jr D. Histamine: a mediator of inflammation. J Allergy Clin Immunol 2003; 112 (4 Suppl. 1): S53-9
33. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003; 112: 15-22
34. 2 receptors in peripheral blood mononuclear cells: comparison with IL-1 receptor antagonist. J Clin Invest 1993; 92: 281-7
35. Meretey K, Falus A, Taga T, et al. Histamine influences the expression of the interleukin-6 receptor on human lymphoid, monocytoid and hepatoma cell lines. Agents Actions 1991; 33: 189-91
36. Jeannin P, Delneste Y, Gosset P, et al. Histamine induces interleukin-8 secretion by endothelial cells. Blood 1994; 84: 2229-33
37. Jutel M, Watanabe T, Akdis M, et al. Immune regulation by histamine. Curr Opin Immunol 2002; 14: 735-40
38. 2 receptors. Nature 2001; 413: 420-5
39. Moriyasu S, Yamamoto K, Kureyama N, et al. Involvement of histamine released from mast cells in acute radiation dermatitis in mice. J Pharmacol Sci 2007; 104: 187-90
40. 1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-98
41. 1 receptor antagonists. Eur J Pharmacol 2006; 530: 205-14
42. 1 receptor. Eur Pharmacol 2002; 449: 229-37
43. 1 receptors. In: XIX European Academy of Allergology and Clinical Immunology; 2000 Jul 1-5; Lisbon. Allergy 2000; 55 Suppl. 63: S279
44. 1 histamine receptors: contribution of Lys191 and Thr194. Mol Pharmacol 2002; 61: 391-9
45. Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacology 2005; 5: 8
46. 1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 2000; 50: 345-52
47. 1 receptor. Int Arch Allergy Immunol 2004; 135: 313-8 48.
48. Cardelús I, Antón F, Beleta J, et al. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur J Pharmacol 1999; 374: 249-54
49. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56: 7-13
50. 1 antagonists: receptor affinity versus selectivity. Inflamm Res 2003; 52 Suppl. 1: S49-50
51. Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005; 65: 341-84
52. 1 drugs. Allerg Immunol (Paris) 2006; 38: 347-50
53. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369-77
54. Genovese A, Patella V, De Crescenzo G, et al. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human FcεRI+ cells. Clin Exp Allergy 1997; 27: 559-67
55. Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy 2004; 34: 1342-8
56. Cyr MM, Baatjes AJ, Hayes LM, et al. The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: a placebo-controlled randomized study. In: 58th Annual Meeting of the American Academy of Allergy, Asthma & Immunology; 2002 Mar 1-6; New York. J Allergy Clin Immunol 2002; 109 Suppl. 1: S117
57. Molet S, Gosset P, Lassalle P, et al. Inhibitor activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997; 27: 1167-74
58. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995; 4: 272-6
59. 2-receptor antagonists. Exp Dermatol 2000; 9: 118-24
60. Ciprandi G, Tosca MA, Milanese M, et al. Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism. Eur Ann Allergy Clin Immunol 2004; 36: 67-72
61. 1-receptors. J Immunol 2001; 166: 4083-91
62. Vancheri C, Mastruzzo C, Tomaselli V, et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc 2005; 26: 292-8
63. Asano K, Kanai K, Suzaki H. Supressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung 2004; 54: 436-43
64. Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002; 32: 1187-92
65. Wu P, Mitchell S, Walsh GM. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy 2005; 35: 1073-9
66. 1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004; 114: 1176-82
67. Petecchia L, Serpero L, Silvestri M, et al. The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine. Am J Rhinol 2006; 20: 445-9
68. Tworek D, Bochénska-Marciniak M, Kupczyk M, et al. The effects of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18, and TGF beta in patients suffering from seasonal allergic rhinitis. Pulm Pharmacol Ther 2007; 20: 244-9
69. (q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-42
70. 11C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 2005; 61: 16-26
71. 1-antagonists. Drug Metab Dispos 2003; 31: 312-8
72. 1 antagonists measured by positron emission tomography. Br J Pharmacol 1995; 116: 1649-55
73. 1-receptor antagonist. J Med Chem 1998; 41: 853-63
74. Timmerman H. Why are non-sedating antihistamines non-sedating? Clin Exp Allergy 1999; 29 Suppl. 3: 13-8
75. 1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos 2004; 32: 519-24
76. Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepostatine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol 2004; 29 (5): 526-32
77. 11C- doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890-900
78. Ridout F, Shamsi Z, Meadows R, et al. A single-center, randomized, double-blind, placebo-controlled, crossover investigation of fexofenadine hydrochloride 180mg alone and with alcohol, with hydroxyzine hydrochloride 50mg as a positive internal control, on aspects of cognitive and psychomotor function related to driving a car. Clin Ther 2003; 25: 1518-38
79. Vuurman EFPM, Rikken GH, Muntjewerff ND, et al. Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur J Clin Pharmacol 2004; 60: 307-13
80. Kay G. No sedation or performance impairment with desloratadine, a novel antihistamine [abstract]. Ann Allergy Asthma Immunol 2001; 86 Suppl.: 84
81. Scharf MB, Kay G, Rikken GH, et al. Desloratadine has no effect on wakefulness or psychomotor performance. In: XIX European Academy of Allergology and Clinical Immunology; 2000 Jul 1-5; Lisbon. Allergy 2000; 55 Suppl. 63: 280
82. Rikken GH, Scharf MB, Danzig MR, et al. Desloratadine and alcohol co-administration: no increase in impairment of performance over that induced by alcohol alone. In: XIX European Academy of Allergology and Clinical Immunology; 2000 Jul 1-5; Lisbon. Allergy 2000; 55 Suppl. 63: S277
83. 1-receptor antagonists in the elderly. Ann Allergy Asthma Immunol 1999; 82: 157-60
84. 1 receptor antagonist. 2nd communication: lack of central nervous system effects. Arzneimittelforschung 2000; 50: 441-8
85. Banfield C, Padhi D, Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine [abstract]. J Allergy Clin Immunol 2000; 104 Suppl. P2: S383
86. Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). Int J Clin Pract 2004; 58: 109-18
87. Day JH, Briscoe MP, Rafeiro E, et al. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the Environmental Exposure Unit. Allergy Asthma Proc 2005; 26: 275-82
88. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004; 114: 838-44
89. Layton D, Wilton LV, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006; 29: 897-909
90. Verster JC, de Weert AM, Bijtjes SIR, et al. Driving ability after acute and subchronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2003; 169: 84-90
91. Hindmarch I, Johnson S, Meadows R, et al. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and a placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin 2001; 17: 241-55
92. Gandon JM, Allain H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002; 54: 51-8
93. Verster JC, Volkerts ER, van Oosterwijck AWAA, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003; 111: 623-7
94. Molimard M, Diquet B, Strolin Benedetti M. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004; 18: 399-411
95. Baltes E, Coupez R, Giezek H, et al. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001; 15: 269-77
96. US FDA Center for Drug Evaluation and Research. Approval package for: application number 21-165. Pharmacology review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2001/21-165_Clarinex_pharmr_P1.pdf [Accessed 2008 Feb 18]
97. 14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001; 57: 571-82
98. Ghosal A, Yuan Y, Hapangama N, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm Drug Dispos 2004; 25: 243-52
99. US FDA Center for Drug Evaluation and Research. Approval package for: application number 21-165. Clinical pharmacology and biopharmaceutics review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2001/21- 165_Clarinex_biopharmr_P2.pdf [Accessed 2008 Feb 18]
100. 1 antihistamines. Int J Clin Pharmacol Ther 1998; 36: 292-300
101. Nicolas JM. The metabolic profile of second-generation antihistamines. Allergy 2000; 55 Suppl. 60: 46-52
102. Affrime M, Gupta S, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41 Suppl. 1: 13-9
103. 1-antihistamines in the skin. J Allergy Clin Immunol 2002; 110: 777-83
104. Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56: 388-94
105. Purohit A, Duvernelle C, Melac M, et al. Twenty-four hours of activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol 2001; 86: 387-92
106. Grant JA, Riethusien JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88: 190-7
107. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99: S798-806
108. Devillier P, Bousquet J. Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy? Clin Exp Allergy 2007; 37: 400-14
109. US FDA Center for Drug Evaluation and Research. Draft guidance for industry. Allergic rhinitis: clinical development programs for drug products [online]. Available from URL: http://www.fda.gov/cder/guidance/2718dft.htm [Accessed 2008 Feb 18]
110. Day JH, Briscoe M, Rafeiro E, et al. Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001; 87: 474-81
111. Day JH, Briscoe MP, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol 1998; 101: 638-45
112. Day JH, Briscoe MP, Clark RH, et al. Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79: 163-72
113. Horak F, Jäger S, Berger U. Onset and duration of the effects of three antihistamines in current use - astemizole, loratadine and terfenadine forte - studied during prolonged controlled allergen challenges in volunteers. J Int Med Res 1992; 20: 422-34
114. Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit: the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004; 6: 891-902
115. Frossard N, Lacronique J, Melac M, et al. Onset of action on the nasal antihistaminic effect of cetirizine and loratadine in patients with allergic rhinitis. Allergy 1997; 52: 205-9
116. Day JH, Briscoe MP, Rafeiro E, et al. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis. Allergy Asthma Proc 2004; 25: 59-68
117. Devillier P. Comparing the new antihistamines: the role of pharmacological parameters. Clin Exp Allergy 2005; 36: 5-7
118. Tillement J-P. Pharmacological profile of the new antihistamines. Clin Exp Allergy Rev 2005; 5: 7-11
119. Passalacqua G, Guerra L, Compalati E, et al. Comparison of the effects in the nose and skin of a single dose of desloratadine and levocetirizine over 24 hours. Int Arch Allergy Immunol 2004; 135: 143-7
120. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Comm 2000; 273: 251-60
121. Cvetkovic M, Leak B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27: 866-71
122. Wang E-J, Casciano CN, Clement RP, et al. Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 2001; 29: 1080-3
123. Wang Z, Hamman MA, Huang S-M, et al. Effect of St. John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 414-20
124. van Heeswijk RP, Bourbeau M, Campbell P, et al. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 2006; 46: 758-67
125. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005; 77: 170-7
126. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81: 362-70
127. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41: 311-8
128. Barecki ME, Casciano CN, Johnson WW, et al. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001; 29: 1173-5
129. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetics/ pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 2004; 44: 1252-9
130. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001; 23: 451-66
131. Banfield C, Hunt T, Reyderman L, et al. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41 Suppl. 1: 29-35
132. Khalilieh S, Krishna G, Marino M, et al. Lack of an interaction with coadministration of desloratadine and cimetidine. Ann Allergy Asthma Immunol 2002; 88: 110
133. Banfield C, Herron J, Keung A, et al. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41 Suppl. 1: 37-44
134. Milne RW, Larsen LA, Jørgensen KL, et al. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res 2000; 17: 1511-5
135. Tannergren C, Knutson T, Knutson L, et al. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion techmines nique Br J Clin Pharmacol 2003; 55: 182-90
136. Peytavin G, Gauran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. Eur J Clin Pharmacol 2005; 61: 267-73
137. Tsuruoka S, Ioka T, Wakaumi M, et al. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 2006; 79: 389-96
138. Horita Y, Kanaya H, Uno Y, et al. A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. Jpn Heart J 2004; 45: 1049-56
139. Gupta SK, Kantesaria B, Banfield C, et al. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol 2007; 64: 174-84
140. Gupta S, Khalilieh S, Kantesaria B, et al. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br J Clin Pharmacol 2007; 63: 534-40
141. Simons FER, Bergman JN, Watson WTA, et al. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996; 98: 1062-4
142. Cranswick N, Turziková J, Fuchs M, et al. Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile. Int J Clin Pharmacol Ther 2005; 43: 172-7
143. Simons FER, on behalf of the ETAC Study Group. Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective. Pediatr Allergy Immunol 2005; 16: 97-103
144. Simons FER, Simons KJ. Levocetirizine: pharmacokinetics and pharmacodynamics in children age 6 to 11 years. J Allergy Clin Immunol 2005; 116: 355-61
145. Affrime M, Banfield C, Gupta S, et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet 2002; 41 Suppl. 1: 21-8
146. Gupta SK, Kantesaria B, Wang Z. Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment. J Clin Pharmacol 2007; 47: 1283-91
147. 1 receptor antagonists. Clin Pharmacokinet 1999; 36: 329-52
148. Prenner B, Kim K, Gupta S, et al. Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert Opin Drug Saf 2006; 5: 211-23